Opexa Therapeutics (OPXA) Misses Q2 EPS by 7c
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Opexa Therapeutics (NASDAQ: OPXA) reported Q2 EPS of ($0.30), $0.07 worse than the analyst estimate of ($0.23).
For earnings history and earnings-related data on Opexa Therapeutics (OPXA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Twitter's (TWTR) 'Underweight' Rating Reiterated at Morgan Stanley
- Vascular Solutions (VASC) Tops Q3 EPS by 1c; Issues Solid Outlook
- Compass Minerals (CMP) Misses Q3 EPS by 1c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!